Browse LMOD1

Summary
SymbolLMOD1
Nameleiomodin 1 (smooth muscle)
Aliases 64kD; 1D; SM-LMOD; SMLMOD; 64 kDa autoantigen 1D; 64 kDa autoantigen 1D3; 64 kDa autoantigen D1; leimodin 1 ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, myofibril, sarcomere Cytoplasm, cytoskeleton Note=Colocalizes with actin filaments in sarcomeres.
Domain PF03250 Tropomodulin
PF02205 WH2 motif
Function

Mediates nucleation of actin filaments.

> Gene Ontology
 
Biological Process GO:0003012 muscle system process
GO:0006936 muscle contraction
GO:0007015 actin filament organization
GO:0008064 regulation of actin polymerization or depolymerization
GO:0008154 actin polymerization or depolymerization
GO:0010639 negative regulation of organelle organization
GO:0010927 cellular component assembly involved in morphogenesis
GO:0030041 actin filament polymerization
GO:0030042 actin filament depolymerization
GO:0030239 myofibril assembly
GO:0030832 regulation of actin filament length
GO:0030833 regulation of actin filament polymerization
GO:0030834 regulation of actin filament depolymerization
GO:0030835 negative regulation of actin filament depolymerization
GO:0030837 negative regulation of actin filament polymerization
GO:0030838 positive regulation of actin filament polymerization
GO:0031032 actomyosin structure organization
GO:0031333 negative regulation of protein complex assembly
GO:0031334 positive regulation of protein complex assembly
GO:0032271 regulation of protein polymerization
GO:0032272 negative regulation of protein polymerization
GO:0032273 positive regulation of protein polymerization
GO:0032535 regulation of cellular component size
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0032984 macromolecular complex disassembly
GO:0042692 muscle cell differentiation
GO:0043241 protein complex disassembly
GO:0043242 negative regulation of protein complex disassembly
GO:0043244 regulation of protein complex disassembly
GO:0043254 regulation of protein complex assembly
GO:0043624 cellular protein complex disassembly
GO:0044089 positive regulation of cellular component biogenesis
GO:0045010 actin nucleation
GO:0051146 striated muscle cell differentiation
GO:0051258 protein polymerization
GO:0051261 protein depolymerization
GO:0051493 regulation of cytoskeleton organization
GO:0051494 negative regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0051693 actin filament capping
GO:0051694 pointed-end actin filament capping
GO:0055001 muscle cell development
GO:0055002 striated muscle cell development
GO:0090066 regulation of anatomical structure size
GO:1901879 regulation of protein depolymerization
GO:1901880 negative regulation of protein depolymerization
Molecular Function GO:0003779 actin binding
GO:0005523 tropomyosin binding
Cellular Component GO:0005865 striated muscle thin filament
GO:0005884 actin filament
GO:0015629 actin cytoskeleton
GO:0030016 myofibril
GO:0030017 sarcomere
GO:0036379 myofilament
GO:0043292 contractile fiber
GO:0044449 contractile fiber part
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-397014: Muscle contraction
R-HSA-445355: Smooth Muscle Contraction
Summary
SymbolLMOD1
Nameleiomodin 1 (smooth muscle)
Aliases 64kD; 1D; SM-LMOD; SMLMOD; 64 kDa autoantigen 1D; 64 kDa autoantigen 1D3; 64 kDa autoantigen D1; leimodin 1 ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LMOD1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolLMOD1
Nameleiomodin 1 (smooth muscle)
Aliases 64kD; 1D; SM-LMOD; SMLMOD; 64 kDa autoantigen 1D; 64 kDa autoantigen 1D3; 64 kDa autoantigen D1; leimodin 1 ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LMOD1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLMOD1
Nameleiomodin 1 (smooth muscle)
Aliases 64kD; 1D; SM-LMOD; SMLMOD; 64 kDa autoantigen 1D; 64 kDa autoantigen 1D3; 64 kDa autoantigen D1; leimodin 1 ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LMOD1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.8040.0207
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7570.301
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.8310.12
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.7430.339
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5310.841
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.0160.75
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.230.594
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4740.598
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0850.934
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9810.423
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.8640.246
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5130.0273
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LMOD1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.12.78.40.12
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.13.47.70.176
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLMOD1
Nameleiomodin 1 (smooth muscle)
Aliases 64kD; 1D; SM-LMOD; SMLMOD; 64 kDa autoantigen 1D; 64 kDa autoantigen 1D3; 64 kDa autoantigen D1; leimodin 1 ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LMOD1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLMOD1
Nameleiomodin 1 (smooth muscle)
Aliases 64kD; 1D; SM-LMOD; SMLMOD; 64 kDa autoantigen 1D; 64 kDa autoantigen 1D3; 64 kDa autoantigen D1; leimodin 1 ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LMOD1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LMOD1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLMOD1
Nameleiomodin 1 (smooth muscle)
Aliases 64kD; 1D; SM-LMOD; SMLMOD; 64 kDa autoantigen 1D; 64 kDa autoantigen 1D3; 64 kDa autoantigen D1; leimodin 1 ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LMOD1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLMOD1
Nameleiomodin 1 (smooth muscle)
Aliases 64kD; 1D; SM-LMOD; SMLMOD; 64 kDa autoantigen 1D; 64 kDa autoantigen 1D3; 64 kDa autoantigen D1; leimodin 1 ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LMOD1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLMOD1
Nameleiomodin 1 (smooth muscle)
Aliases 64kD; 1D; SM-LMOD; SMLMOD; 64 kDa autoantigen 1D; 64 kDa autoantigen 1D3; 64 kDa autoantigen D1; leimodin 1 ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LMOD1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLMOD1
Nameleiomodin 1 (smooth muscle)
Aliases 64kD; 1D; SM-LMOD; SMLMOD; 64 kDa autoantigen 1D; 64 kDa autoantigen 1D3; 64 kDa autoantigen D1; leimodin 1 ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LMOD1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.